TABLE 1.

Model Inputs

Parameter		Value		Source
Efficacy inputs
		Fingolimod	IM IFNβ-1a
Relative risk of disability progression		0.68	0.79	ICER (2017)7
Relative rate of relapse		0.46	0.83
Utility inputs
Health-state utility by EDSS	0	0.8752		ICER (2017)7 Based on: Mauskopf et al. (2016)27
	1	0.8342
	2	0.7802
	3	0.6946
	4	0.6253
	5	0.5442
	6	0.4555
	7	0.3437
	8	0.0023
	9	-0.1701
Adjustment to SPMS	-0.0437
Relapse (per event)	Mild/moderate	-0.091		ICER (2017)7 Based on: Oleen-Burkey et al. (2012)36
	Severe	-0.302
Cost inputs, $
Health-state costs by EDSS	0	1,859		ICER (2017) inflated to 2017 USD using the U.S. Consumer Price Index for medical care7 Based on: Kobelt et al. (2006)37
	1	3,195
	2	4,531
	3	5,866
	4	7,203
	5	8,539
	6	9,875
	7	11,211
	8	12,547
	9	13,883
Relapse (per event)		1,771
		Fingolimod	IM IFNβ-1a
Annual medication cost, $		87,025	82,012	WAC (2017)30
Annual administration and monitoring costs	Year 1	172	58	ICER (2017) inflated to 2017 USD using the U.S. Consumer Price Index for medical care7
	Year 2+	76	39
LOE inputs
		Fingolimod	IM IFNβ-1a
Cycle number of LOE		4	10	FDA Orange Book and Avonex32,33
Price reduction on LOE, %	Year 1	80	27	IMS (2016)20 WAC (2017)30
	Year 2	85
	Year 3+	90
Patients switching to generic versions on LOE, %		88	88	IMS (2016)20

EDSS = Expanded Disability Status Scale; FDA = U.S. Food and Drug Administration; ICER = Institute for Clinical and Economic Review; IM IFNβ-1a = intramuscular interferon beta-1a; LOE = loss of exclusivity; SPMS = secondary progressive multiple sclerosis; USD = U.S. dollars; WAC = wholesale acquisition cost.